New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
11:09 EDTLL, RDN, LO, FTNT, PSEC, SD, MBI, TWTR, SRPT, GNCOptions with increasing implied volatility
Options with increasing implied volatility: LL SRPT TWTR MBI SD PSEC FTNT LO RDN GNC
News For LL;SRPT;TWTR;MBI;SD;PSEC;FTNT;LO;RDN;GNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
October 20, 2014
11:37 EDTTWTRStocks with call strike movement; X TWTR
Subscribe for More Information
09:09 EDTSRPTEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
05:54 EDTSDStocks with implied volatility movement; HLD SD
Stocks with implied volatility movement; Herbalife (HLF) 109, SandRidge Energy (SD) 97 according to iVolatility.
October 19, 2014
16:44 EDTSRPTEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTSRPTCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
16:01 EDTTWTROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
14:50 EDTSRPTBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
12:17 EDTTWTRMark Cuban says buying Netflix shares, sees company as M&A target
Subscribe for More Information
09:46 EDTSRPTSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on
Subscribe for More Information
09:17 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
05:51 EDTSDStocks with implied volatility movement; SD SAN
Subscribe for More Information
October 16, 2014
18:36 EDTSRPTOn The Fly: After Hours Movers
Subscribe for More Information
18:16 EDTSRPTSarepta up 10.6% following publication of Ebola phase 1 clinical study
16:44 EDTTWTRTwitter launches Audio Card with third-party streaming services
Subscribe for More Information
16:13 EDTSRPTSarepta announces publication of Ebola, Marburg Phase I clinical study results
Sarepta Therapeutics announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers, which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta’s advanced and proprietary PMOplus chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288.
16:12 EDTLLPoint72 Asset reports 5.2% passive stake in Lumber Liquidators
Subscribe for More Information
16:01 EDTTWTROptions Update; October 16, 2014
Subscribe for More Information
10:54 EDTTWTRTwitter October weekly volatility elevated into Q3 and growth outlook
Twitter October weekly call option implied volatility is at 94, November is at 75, December is at 58, January at 54; compared to its 26-week average of 54 according to Track Data, suggesting large near term price movement into the expected release of Q3 results after the market close on October 27.
09:39 EDTTWTRActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use